Literature DB >> 16950022

Chapter 10: New dimensions in cervical cancer screening.

Jack Cuzick1, Marie Helene Mayrand, Guglielmo Ronco, Peter Snijders, Jane Wardle.   

Abstract

Human papillomavirus (HPV) testing has clearly demonstrated a higher sensitivity but somewhat lower specificity than cytology. However, there are still issues regarding how best to use it in primary screening. In countries where cytology is of good quality, the most interesting possibility for primary screening is to use HPV testing as the sole screening modality with cytology reserved for triage of HPV-positive women. In countries with a less established infrastructure, however, use of HPV alone would also be attractive, although rapid, simple tests followed by immediate treatment are needed to minimize the number of visits and make best use of limited resources. Several approaches to deal with the lower specificity of HPV testing are also examined. These include HPV typing with a different management strategy for HPV-16 and -18/45, use of viral load to exclude infections unlikely to be associated with > or =CIN-2, and markers of proliferative lesions such as p16 and mRNA or cell-cycle markers such as cdc6 or the mcm5 proteins. Micro-array studies offer the prospect of discovering new, better DNA- or RNA-based diagnostics. The fact that HPV is a sexually transmitted infection may lead to anxiety and concerns about sexual relationships and these issues are also discussed. Ongoing HPV studies are identified and briefly reviewed.

Entities:  

Mesh:

Year:  2006        PMID: 16950022     DOI: 10.1016/j.vaccine.2006.05.122

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  31 in total

1.  Trade-offs in cervical cancer prevention: balancing benefits and risks.

Authors:  Natasha K Stout; Jeremy D Goldhaber-Fiebert; Jesse D Ortendahl; Sue J Goldie
Journal:  Arch Intern Med       Date:  2008-09-22

2.  Clinical impact of the analytical specificity of the hybrid capture 2 test: data from the New Technologies for Cervical Cancer (NTCC) study.

Authors:  Anna Gillio-Tos; Laura De Marco; Francesca Maria Carozzi; Annarosa Del Mistro; Salvatore Girlando; Elena Burroni; Helena Frayle-Salamanca; Paolo Giorgi Rossi; Paola Pierotti; Guglielmo Ronco
Journal:  J Clin Microbiol       Date:  2013-06-26       Impact factor: 5.948

3.  Human papillomavirus viral load expressed as relative light units (RLU) correlates with the presence and grade of preneoplastic lesions of the uterine cervix in atypical squamous cells of undetermined significance (ASCUS) cytology.

Authors:  M Origoni; G Carminati; S Rolla; M Clementi; M Sideri; M T Sandri; M Candiani
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-03-01       Impact factor: 3.267

4.  Human papillomavirus vaccine update.

Authors:  Alisa Ames; Patti Gravitt
Journal:  Curr Infect Dis Rep       Date:  2007-03       Impact factor: 3.725

5.  Hybrid capture vs. PCR screening of cervical human papilloma virus infections. Cytological and histological associations in 1270 women.

Authors:  Sotirios Tsiodras; John Georgoulakis; Aikaterini Chranioti; Zanis Voulgaris; Amanda Psyrri; Angeliki Tsivilika; John Panayiotides; Petros Karakitsos
Journal:  BMC Cancer       Date:  2010-02-22       Impact factor: 4.430

Review 6.  HPV-FASTER: broadening the scope for prevention of HPV-related cancer.

Authors:  F Xavier Bosch; Claudia Robles; Mireia Díaz; Marc Arbyn; Iacopo Baussano; Christine Clavel; Guglielmo Ronco; Joakim Dillner; Matti Lehtinen; Karl-Ulrich Petry; Mario Poljak; Susanne K Kjaer; Chris J L M Meijer; Suzanne M Garland; Jorge Salmerón; Xavier Castellsagué; Laia Bruni; Silvia de Sanjosé; Jack Cuzick
Journal:  Nat Rev Clin Oncol       Date:  2015-09-01       Impact factor: 66.675

7.  RNA (E6 and E7) assays versus DNA (E6 and E7) assays for risk evaluation for women infected with human papillomavirus.

Authors:  Paola Cattani; Alessia Siddu; Sara D'Onghia; Simona Marchetti; Rosaria Santangelo; Valerio G Vellone; Gian Franco Zannoni; Giovanni Fadda
Journal:  J Clin Microbiol       Date:  2009-04-29       Impact factor: 5.948

Review 8.  Cervical cancer prevention--cervical screening: science in evolution.

Authors:  Mahboobeh Safaeian; Diane Solomon; Philip E Castle
Journal:  Obstet Gynecol Clin North Am       Date:  2007-12       Impact factor: 2.844

9.  Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination.

Authors:  Jeremy D Goldhaber-Fiebert; Natasha K Stout; Joshua A Salomon; Karen M Kuntz; Sue J Goldie
Journal:  J Natl Cancer Inst       Date:  2008-02-26       Impact factor: 13.506

Review 10.  New paradigms in cervical cancer prevention: opportunities and risks.

Authors:  Guglielmo Ronco; Paolo Giorgi Rossi
Journal:  BMC Womens Health       Date:  2008-12-17       Impact factor: 2.809

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.